Giusti Laura, Iacconi Pietro, Ciregia Federica, Giannaccini Gino, Donatini Gian Luca, Basolo Fulvio, Miccoli Paolo, Pinchera Aldo, Lucacchini Antonio
Department of Psychiatry, Neurobiology, Pharmacology and Biotechnology, University of Pisa, Pisa, Italy.
J Proteome Res. 2008 Sep;7(9):4079-88. doi: 10.1021/pr8000404. Epub 2008 Jul 30.
At present, the clinical and pathological analysis used in the diagnosis of papillary thyroid cancer (PTC) are insufficient to discern tumor behavior, and new diagnostic and prognostic markers need to be identified. In this study, we performed a comparative proteome analysis to examine the global changes of fine needle aspiration fluid (FNA) protein patterns of two variants of malignant PTC (classical variant PTC (cPTC) and tall cell variant PTC (TCV)) with respect to the controls. Changes in protein expression were identified using two-dimensional electrophoresis (2DE) and peptide mass fingerprinting via MALDI-TOF mass spectrometry (MS), as well as Western blot analysis. A statistical significant up-regulation of 17 protein spots in cPTC and/or TCV with respect to controls was demonstrated. These proteins included transthyretin precursor (TTR), ferritin light chain (FLC), proteasome activator complex subunit 1 and 2, alpha-1-antitrypsin precursor, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), lactate dehydrogenase chain B (LDH-B), apolipoprotein A1 precursor (Apo-A1), annexin A1, DJ-1 protein and cofilin-1. In addition, 12 protein spots were found exclusively in cPTC and three exclusively in TCV. These latter proteins (ferritin heavy chain (FHC), peroxiredoxin 1 (PRX1) and 6-phosphogluconate dehydrogenase (6-PDGH)) correspond to stress response proteins and, until now, had not been described in thyroid tumors. These findings illustrate the potential use of FNA proteomics to identify protein changes associated with thyroid cancer and to advance potential protein biomarkers in the diagnostic classification of the disease.
目前,用于诊断甲状腺乳头状癌(PTC)的临床和病理分析不足以辨别肿瘤行为,需要鉴定新的诊断和预后标志物。在本研究中,我们进行了一项比较蛋白质组分析,以检查恶性PTC的两种变体(经典变体PTC(cPTC)和高细胞变体PTC(TCV))相对于对照的细针穿刺抽吸液(FNA)蛋白质模式的整体变化。使用二维电泳(2DE)、基质辅助激光解吸电离飞行时间质谱(MALDI-TOF MS)的肽质量指纹图谱以及蛋白质印迹分析来鉴定蛋白质表达的变化。结果表明,相对于对照,cPTC和/或TCV中有17个蛋白点存在统计学上的显著上调。这些蛋白质包括转甲状腺素蛋白前体(TTR)、铁蛋白轻链(FLC)、蛋白酶体激活复合物亚基1和2、α-1-抗胰蛋白酶前体、甘油醛-3-磷酸脱氢酶(GAPDH)、乳酸脱氢酶B链(LDH-B)、载脂蛋白A1前体(Apo-A1)、膜联蛋白A1、DJ-1蛋白和丝切蛋白-1。此外,分别在cPTC中发现了12个蛋白点,在TCV中发现了3个蛋白点。这些后发现的蛋白质(铁蛋白重链(FHC)、过氧化物还原酶1(PRX1)和6-磷酸葡萄糖酸脱氢酶(6-PDGH))对应于应激反应蛋白,并且到目前为止,尚未在甲状腺肿瘤中被描述。这些发现说明了FNA蛋白质组学在识别与甲状腺癌相关的蛋白质变化以及推进该疾病诊断分类中的潜在蛋白质生物标志物方面的潜在用途。